RxDoctor Payments Data

Elizabeth Huff, MD

Internal Medicine · American Fork, UTNPI 1427108240

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 73 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$477
  • Tandem Diabetes Care, Inc.$297
  • Medtronic$231
  • Dexcom, Inc.$126
  • Lilly USA, LLC$62
  • Xeris Pharmaceuticals, Inc.$49
  • plus $249 from 10 others

What the payments were for

  • Food & beverage$1,47999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 75th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$24,624
Medicare patients
86
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide408$547,815
JardianceEmpagliflozin191$236,487
OzempicSemaglutide49$79,539
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$50,124
TrulicityDulaglutide31$45,665
FarxigaDapagliflozin Propanediol39$37,405
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog43$23,139
Tresiba Flextouch U-100Insulin Degludec19$13,898
Novolog FlexpenInsulin Aspart30$10,544
Humalog Kwikpen U-100Insulin Lispro23$7,540
Insulin Aspart FlexpenInsulin Aspart18$7,287
NovologInsulin Aspart16$7,169
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$3,712
HumalogInsulin Lispro12$3,485
LantusInsulin Glargine,hum.Rec.Anlog13$2,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$62$596,964451 claims
Novo NordiskOzempic, Novolog$21$86,70865 claims
Sanofi-aventis U.S. LLCLantus$22$2,62713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 496 internal medicine providers in Utah.

Other internal medicine in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →